ClinicalTrials.gg
CompletedNCT07128654Updated Nov 17, 2025

A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers

A Phase 1 interventional study of CTL02 and CTL0201 in Healthy, sponsored by Celltrion. Completed at 1 site in South Korea. Open to participants aged 19 Days to 55 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Celltrion · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Days to 55 Days
Sex
All
01

Study summary

This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the safety and pharmacokinetics after co-administration of CTL0201 and CTL0202 or administration of CT-L02 in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Days to 55 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participant aged 19 to 55 years, at screening
  • A participant who has a (BMI) of 18.0\~29.9 kg/m2, at screening
  • A participant who is judged to be eligible to participate by the results of screening tests (vital signs, clinical laboratory tests, 12-lead , etc.) by the principal investigator

Exclusion criteria

Exclusion Criteria:

  • A participant who has taken drugs that induce or inhibit drug metabolizing enzymes
  • A participant who has participated in other clinical trials or bioequivalence studies within 6 months prior to the first dose of the drug
  • A participant who has a history of gastrointestinal surgery that may affect drug absorption
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Arm A

    CTL02

    Drug: CTL02

  • Active comparator
    Arm B

    Co-administration of CTL0201 and CTL0202

    Drug: CTL0201 · Drug: CTL0202

Interventions

  • DrugCTL02

    FDC tablet, single dose, oral administration

  • DrugCTL0201

    Nesina, tablet, single dose, oral administration

  • DrugCTL0202

    Jardiance, tablet, single dose, oral administration

06

What researchers measure

Primary outcomes

  1. AUCt (Area under the plasma concentration-time curve)

    Time frame: 0(Pre-dose), 0.17, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, 48, 72hrs

  2. Cmax (Peak Plasma Concentration)

    Time frame: 0(Pre-dose), 0.17, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, 48, 72hrs

07

Study locations

1 site
  • H+ Yangji Hospital
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Oct 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 19, 2025
StartActual
Sep 17, 2025
Primary completionActual
Oct 5, 2025
CompletionActual
Oct 26, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07128654
Lead sponsor
Celltrion
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Sep 17, 2025
Primary completion
Oct 5, 2025
Completion
Oct 26, 2025
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion